GE Equity is a division of General Electric that focuses on maximizing returns on investment capital through equity investing. It specializes in acquiring minority ownership stakes in established companies with significant growth potential. The division pursues various investment strategies, including growth capital, buy-out co-investments, secondary direct purchases, recapitalizations, and limited partner investments. Leveraging GE's extensive industry knowledge and global reach, GE Equity seeks to identify and capitalize on high-potential opportunities across multiple sectors. By combining financial acumen with operational expertise, GE Equity plays a crucial role in enhancing the overall value of General Electric's investment portfolio.
At Achillion, we are driven to transform the lives of patients and families affected by diseases of the complement system, an integral part of the innate immune system. Scientific and clinical evidence has implicated the complement system, and specifically the complement Alternative Pathway (AP), in numerous devastating diseases and conditions. Our principal focus at Achillion is to advance our clinical-stage portfolio of orally administered factor D inhibitors into late-stage development and potential commercialization for patients with devastating disorders of the complement system.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.